Notice: This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CUR vs. AIM, PMCB, APTO, TSBX, BCDA, KLTO, BCLI, COEP, CERO, and EVAXShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Aptose Biosciences (APTO), Turnstone Biologics (TSBX), BioCardia (BCDA), Klotho Neurosciences (KLTO), Brainstorm Cell Therapeutics (BCLI), Coeptis Therapeutics (COEP), CERo Therapeutics (CERO), and Evaxion Biotech A/S (EVAX). These companies are all part of the "medical" sector. Neuralstem vs. AIM ImmunoTech PharmaCyte Biotech Aptose Biosciences Turnstone Biologics BioCardia Klotho Neurosciences Brainstorm Cell Therapeutics Coeptis Therapeutics CERo Therapeutics Evaxion Biotech A/S Neuralstem (NASDAQ:CUR) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Does the media refer more to CUR or AIM? In the previous week, AIM ImmunoTech had 9 more articles in the media than Neuralstem. MarketBeat recorded 9 mentions for AIM ImmunoTech and 0 mentions for Neuralstem. AIM ImmunoTech's average media sentiment score of 0.08 beat Neuralstem's score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the news media. Company Overall Sentiment Neuralstem Neutral AIM ImmunoTech Neutral Do analysts prefer CUR or AIM? AIM ImmunoTech has a consensus price target of $2.75, indicating a potential upside of 1,347.37%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts plainly believe AIM ImmunoTech is more favorable than Neuralstem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuralstem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CUR or AIM? Neuralstem received 219 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 83.10% of users gave AIM ImmunoTech an outperform vote while only 66.83% of users gave Neuralstem an outperform vote. CompanyUnderperformOutperformNeuralstemOutperform Votes27866.83% Underperform Votes13833.17% AIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90% Which has stronger valuation & earnings, CUR or AIM? Neuralstem has higher revenue and earnings than AIM ImmunoTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuralstem$260K14.13-$4.93MN/AN/AAIM ImmunoTech$190K63.78-$28.96M-$0.47-0.40 Is CUR or AIM more profitable? AIM ImmunoTech has a net margin of -12,594.21% compared to Neuralstem's net margin of -39,417.64%. Neuralstem's return on equity of -170.51% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Neuralstem-39,417.64% -170.51% -110.16% AIM ImmunoTech -12,594.21%-421.73%-147.54% Which has more volatility & risk, CUR or AIM? Neuralstem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CUR or AIM? 38.3% of Neuralstem shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryNeuralstem and AIM ImmunoTech tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.68M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.1317.19Price / Sales14.13415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / Book0.263.894.784.78Net Income-$4.93M-$42.21M$120.31M$225.60M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$1.75-2.8%N/A+200.7%$3.68M$260,000.000.006AIMAIM ImmunoTech2.3673 of 5 stars$0.21-4.1%$2.75+1,209.5%-60.4%$13.39M$190,000.00-0.4720PMCBPharmaCyte Biotech0.4217 of 5 stars$1.69-1.7%N/A-24.8%$12.98MN/A2.612Earnings ReportAPTOAptose Biosciences2.6342 of 5 stars$0.19-2.0%$4.33+2,190.3%-87.7%$11.39MN/A-0.0631News CoverageGap UpTSBXTurnstone Biologics2.8506 of 5 stars$0.47-2.1%$2.13+352.1%-80.2%$10.87M$19.31M-0.1582Positive NewsGap DownBCDABioCardia3.3081 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpKLTOKlotho NeurosciencesN/A$0.44+2.3%N/AN/A$9.35MN/A0.00N/AGap DownBCLIBrainstorm Cell Therapeutics3.993 of 5 stars$1.55+6.9%$30.00+1,835.5%-21.2%$8.84MN/A-0.3040Gap UpCOEPCoeptis Therapeutics0.3751 of 5 stars$0.19+7.4%N/A-83.9%$7.85M$80,000.00-0.612Gap UpCEROCERo TherapeuticsN/A$0.05-10.1%N/AN/A$7.67MN/A0.008High Trading VolumeEVAXEvaxion Biotech A/S3.1513 of 5 stars$1.05-7.9%$11.00+947.6%-86.6%$6.16M$3.30M-3.4849 Related Companies and Tools Related Companies AIM Alternatives PMCB Alternatives APTO Alternatives TSBX Alternatives BCDA Alternatives KLTO Alternatives BCLI Alternatives COEP Alternatives CERO Alternatives EVAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CUR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
